BioInvent International : Interim Report 1 January – 30 September 2016

Third quarter 2016, July - September

• Net sales for July - September 2016 amounted to SEK 0.8 (1.7) million.
• Earnings after tax for July - September 2016: SEK -29 (-23) million.
• Earnings after tax per share for July - September 2016 before and after dilution: -0.10 (-0.14) SEK.
• Cash flow from current operations and investment activities for July - September 2016: SEK -28 (-12) million.

Nine-month report 2016, January - September

• Net sales for January - September 2016 amounted to SEK 40 (5.9) million.
• Earnings after tax for January - September 2016: SEK -55 (-70) million.
• Earnings after tax per share for January - September 2016 before and after dilution: SEK -0.23 (-0.51).
• Liquid funds as of 30 September 2016: SEK 196 (51) million. Cash flow from current operations and investment activities for January - September 2016: SEK -54 (-63) million.

Important events in the third quarter and after the reporting period

• BioInvent announced in July 2016 it had signed an agreement with Alligator Bioscience AB to provide process development and manufacturing services for Alligator's new bispecific antibody, ADC-1015. The agreement is expected to generate revenues of more than SEK 20 million for BioInvent, with the majority in 2017.
• BioInvent announced in September 2016 that it had been granted additional patent protection in Japan, Russia and China for BI-505. These patents cover the use of BI-505 in the treatment of patients previously treated for cancer that have either not responded or subsequently relapsed.

Comments from the CEO
'BioInvent continues to achieve important progress in executing its strategy to deliver new improved immunotherapies to patients and we remain focused on creating long-term shareholder value. With three of our pipeline assets now in clinical trials, BioInvent is in a strong position. Based on the pre-clinical data garnered to date, we believe that the novel mode of action of each of these antibodies have the potential to deliver clear clinical benefits to cancer patients.

A Phase l/ll study of BI-1206, which is primarily being developed for the treatment of chronic lymphatic leukaemia and non-Hodgkin lymphoma, is now open and is expected to begin dosing patients shortly, BI-505 is currently in a Phase II trial in patients with multiple myeloma, an incurable form of blood cancer. In addition, a Phase l/ll study with TB-403, the focus of partnership with Oncurious, was initiated earlier this year.

We are also making important progress with our ground-breaking pre-clinical research. This research is focused on developing a range of novel antibodies that modulate the activity of tumour associated macrophages and regulatory T-cells, (TAMs and T-regs), which suppress the body's immune response to tumours.

New cancer immunotherapies, such as check-point inhibitors, have successfully improved survival rates, though only in relatively limited patient populations thus far. Therefore, the industry is focused on combination therapies to improve these results in more indications and a vaster number of patients. Antibodies that are able to modulate TAMs and T-regs have the potential to further enhance the body's immune response to cancer, and thereby increase the survival rates for patients not responding to current therapies.

BioInvent's partners continue to achieve important product development milestones, as well. ThromboGenics is planning to initiate a Phase l clinical trial with the antibody THR-317, in patients suffering from diabetic macular oedema. Under the agreement with ThromboGenics, BioInvent maintains a 40% ownership of assets. We are evaluating how best to capture the value of this programme from BioInvent's perspective.

With an exciting clinical pipeline, significant on-going pre-clinical research, access to extensive drug development expertise and a sound financial structure, BioInvent is well positioned to deliver a number of novel immunotherapies with the potential to greatly improve the prognosis for cancer patients,' said Michael Oredsson, CEO of BioInvent.

Contact
Any questions regarding this report will be answered by Michael Oredsson, CEO, phone.+46 (0)46 286 85 67, mobile +46 (0)707 18 89 30. The report is also available at www.bioinvent.comThis information is information that BioInvent International AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.40 a.m. CET, on 25 October, 2016.

BioInvent International AB (OMXS: BINV) is focused on developing a first-in-class and best-in-class pipeline of antibody immunotherapeutics against cancer. The company's two lead clinical programmes are BI-505, in Phase II development for multiple myeloma, and BI-1206, in Phase I/II for non-Hodgkin's lymphoma and chronic lymphatic leukaemia. These innovative antibodies have been developed using BioInvent's proprietary technology platform, including its state-of-the-art antibody library, n-CoDeR® and F.I.R.S.T™ technology for selection, screening and identification of antibodies. BioInvent also has its own manufacturing facility for the production of antibodies for research through to late-stage clinical trials. The Company has research collaborations in place with leading academic institutions including Penn Medicine, Cancer Research UK, and the University of Southampton. BioInvent generates revenues from its eight global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma.